FY2025 EPS Forecast for Nuvectis Pharma Lowered by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Research analysts at Roth Capital dropped their FY2025 earnings estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, November 4th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of ($1.19) per share for the year, down from their prior estimate of ($0.97). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at $1.81 EPS.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.20).

Several other research firms have also weighed in on NVCT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Wednesday, October 8th. HC Wainwright lowered their price objective on shares of Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, August 4th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.33.

Nuvectis Pharma Stock Down 3.9%

NASDAQ:NVCT opened at $5.65 on Thursday. The company has a fifty day moving average of $6.23 and a 200-day moving average of $7.55. The firm has a market capitalization of $143.85 million, a P/E ratio of -4.12 and a beta of -0.28. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80.

Insider Buying and Selling

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 72,836 shares of the firm’s stock in a transaction on Monday, October 27th. The stock was acquired at an average price of $6.28 per share, for a total transaction of $457,410.08. Following the purchase, the insider owned 3,136,576 shares of the company’s stock, valued at $19,697,697.28. This trade represents a 2.38% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have acquired 154,770 shares of company stock worth $957,083. Insiders own 30.52% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds have recently bought and sold shares of NVCT. Iridian Asset Management LLC CT grew its stake in shares of Nuvectis Pharma by 8.8% in the 3rd quarter. Iridian Asset Management LLC CT now owns 405,621 shares of the company’s stock worth $2,442,000 after acquiring an additional 32,904 shares in the last quarter. Marex Group plc bought a new stake in shares of Nuvectis Pharma in the 2nd quarter worth $112,000. Bank of America Corp DE grew its stake in shares of Nuvectis Pharma by 417.2% in the 2nd quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock worth $64,000 after acquiring an additional 6,909 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Nuvectis Pharma in the 2nd quarter worth $53,000. Finally, Marshall Wace LLP grew its stake in shares of Nuvectis Pharma by 63.6% in the 2nd quarter. Marshall Wace LLP now owns 63,613 shares of the company’s stock worth $475,000 after acquiring an additional 24,739 shares in the last quarter. 96.77% of the stock is owned by hedge funds and other institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.